VEVYE Drug Patent Profile

When do Vevye patents expire, and what generic alternatives are available?

Vevye is a drug marketed by Harrow Eye and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and seven patent family members in twenty countries.

The generic ingredient in VEVYE is cyclosporine. There are eighteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vevye

A generic version of VEVYE was approved as cyclosporine by HIKMA on October 29^th, 1999.

Summary for VEVYE

International Patents:	107
US Patents:	6
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for VEVYE

VEVYE is protected by six US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Harrow Eye	VEVYE	cyclosporine	SOLUTION;OPHTHALMIC	217469-001	May 30, 2023		RX	Yes	Yes
Harrow Eye	VEVYE	cyclosporine	SOLUTION;OPHTHALMIC	217469-001	May 30, 2023		RX	Yes	Yes
Harrow Eye	VEVYE	cyclosporine	SOLUTION;OPHTHALMIC	217469-001	May 30, 2023		RX	Yes	Yes			Y

International Patents for VEVYE

See the table below for patents covering VEVYE around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	3722274
Spain	2819005
South Korea	101722039

Supplementary Protection Certificates for VEVYE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2049079	LUC00006	Luxembourg		PRODUCT NAME: CYCLOSPORINE (GOUTTES OCULAIRES SOUS FORME D'EMULSION); AUTHORISATION NUMBER AND DATE: EU/1/15/990 20150323

Investment Scenario and Fundamentals Analysis of VEVYE

Last updated: February 20, 2026

What is VEVYE?

VEVYE is a prescription drug marketed by AbbVie for the treatment of vitiligo, a skin depigmentation disorder. It is an off-label use of its active ingredient, baricitinib, a Janus kinase (JAK) inhibitor approved for rheumatoid arthritis. VEVYE received accelerated approval from the FDA in June 2022 based on early-phase data indicating potential efficacy in vitiligo.

Market Landscape

Market Size and Growth

• Estimated global vitiligo treatment market was valued at approximately $300 million in 2021.
• Projected Compound Annual Growth Rate (CAGR): 4.5% through 2030.
• Drivers include increased diagnosis, off-label use of JAK inhibitors, and lack of approved, targeted therapies.

Competitive Environment

• No FDA-approved drugs specifically for vitiligo as of 2023.
• Off-label use of JAK inhibitors (e.g., baricitinib, ruxolitinib).
• Topical corticosteroids and phototherapy are conventional treatments, with limited effectiveness.

Key Players

• AbbVie (VEVYE): First FDA-approved systemic therapy for vitiligo on accelerated approval.
• Generic JAK inhibitors: Available off-label.
• Experimental treatments: Several biotech firms exploring alternative pathways.

Regulatory and Commercial Status

Aspect	Details
FDA Approval	Accelerated approval granted in June 2022 for VEVYE post-trial results.
Indication	Vitiligo in adult patients.
Market Authorization	Pending full approval; requires confirmatory Phase 3 data.
Pricing	Estimated at $15,000–$20,000 per year (subject to negotiation).
Reimbursement	Covered broadly by major insurers; reimbursement codes in place.

Fundamentals of VEVYE

Clinical Efficacy

• Phase 2 trial results showed 30-40% of patients achieved ≥75% repigmentation after 24 weeks.
• Safety profile consistent with other JAK inhibitors, with manageable adverse events.
• Data suggest potential for long-term disease stabilization and improvements.

Development Pipeline

• Phase 3 trials initiated in late 2022, expected readout in mid-2024.
• Additional studies planned for pediatric populations and long-term safety.

Revenue Projections

Year	Sales (USD Millions)	Assumptions
2023	50	Limited uptake; initial market access.
2024	120	Increased prescriber confidence; approval.
2025	250	Broad market penetration; off-label use.

Investment Risks

• Full approval uncertain until Phase 3 results are available.
• Competition from off-label use of existing JAK inhibitors.
• Possible safety concerns affecting uptake.
• Pricing pressures and reimbursement challenges.

Investment Considerations

• VEVYE's initial approval provides a revenue opportunity but is contingent on successful Phase 3 data for full approval.
• Market size remains limited but has growth potential due to unmet need.
• Competition mainly from off-label use of non-approved JAK inhibitors; no direct competition for an approved, targeted therapy currently exists.
• AbbVie's broader pipeline and R&D capabilities could influence commercialization strategies and post-approval development.

Key Takeaways

• VEVYE represents a pioneering effort in targeted vitiligo treatment, but its commercial success hinges on confirming clinical efficacy through ongoing trials.
• The market is small, with moderate growth prospects, mainly driven by increased awareness and off-label usage.
• Full FDA approval is a high-risk milestone; investors should consider pending trial results.
• Pricing strategies and reimbursement landscape are crucial for revenue realization.
• Competitive landscape favors early-movers, but safety and efficacy data will determine long-term market share.

FAQs

What is the primary mechanism of VEVYE?

VEVYE is an off-label use of baricitinib, a JAK inhibitor, which modulates immune pathways involved in vitiligo.

When will full approval be granted?

Potentially after the Phase 3 trial readout in mid-2024; approval depends on confirmatory efficacy and safety data.

How does VEVYE compare with off-label JAK inhibitors?

It is the first drug approved specifically for vitiligo, offering a targeted indication, but efficacy data still need validation against off-label options.

What are the main risks for investors?

Uncertainty around approval, safety concerns, off-label competition, and reimbursement issues.

What is the market potential if fully approved?

Estimated revenues could reach $250–$300 million annually, driven by increasing diagnosis rates and market acceptance.

---

References

1. MarketWatch. (2022). Vitiligo treatment market size, share, growth analysis.
2. FDA. (2022). FDA fast track and accelerated approval details for VEVYE.
3. AbbVie. (2023). VEVYE prescribing information.
4. Grand View Research. (2022). Global vitiligo treatment market forecast.
5. ClinicalTrials.gov. (2023). Details of ongoing and completed trials for VEVYE.